Between January 1 and June 30, 2007, FDA received 85 post-marketing
reports in which patients who switched from Wellbutrin XL 300 mg to
Teva’s bupropion formulation (Budeprion XL 300 mg) experienced an
undesirable effect. Specifically, in 78 of these cases, there was a
reported loss of antidepressant effect following a switch from the
branded to generic product. In addition to the loss of effect, a number
of cases also reported the new onset or worsening of side effects.
www.peoplewho.org